FORM PCT/DO/EO/905 (March 2001)

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.usplo.gov

Portu or 18				Washington, D
U.S. APPLICATION NO.		FIRST NAMED APPLICANT		ATTY. DOCKET NO.
09/674436		KOTAKI	Τ	101136-00021
			INTERNATIONA	L APPLICATION NO.
ARENT FOX KINTS SUITE 600	NER PLOTKIN & KA	HN .	PCT/JF	200/03388
1050 CONNECTICUT AVENUE N W WASHINGTON, DC 20036 5339			I.A. FILING DATE	PRIORITY DATE
WASHINGTON, DC	, 20036 5339		26 MAY 00	31 MAY 99
		İ		00 1111 000
Nombra	N ON MAGANIC		DATE MAILED:	02 JUL 200
NOTIFICATIO		REQUIREMENTS UNDE GNATED/ELECTED OFFI		N THE UNITED
Office as U.S. Basic		by the applicant or the IB to the U. CFR 1.494) an Elected Offic Indication of Small Ention. Translation of the inte	ce (37 CFR 1.495): ntity Status.	
Oath or D	eclaration of inventors(article 19 amendments.		19 amendments into Er	
The Intern	_	amination Report in English and its ernational Preliminary Examination		
the indicated items in p prior to 20 or 30 month	paragraph 3 below. The	g under 35 U.S.C. 371(f) but has re e Basic National Fee and the copy e to avoid abandonment.	of the international app	
		within the period set forth below in		requirements for
torus .	tion of the application i	into English. A processing fee will or 30 months from the priority da		ed.
Tran	slation.	efective for the reasons indicated or		
_		ne translation of the application and s from the priority date (37 CFR 1.		nan the
c. Oath or the apsurch	declaration of the inve pplication (preferably b	intors, in compliance with 37 CFR by the International application num f submitted later than the appropria	1.497(a) and (b), proper other and international fi	iling date). A
	current oath or declarat ated on the attached PC	ion does not comply with 37 CFR	1.497(a) and (b) for the	: reasons
Name .	ge for providing the oa ity date (37 CFR 1.492	th or declaration later than the app	ropriate 20 or 30 month	as from the
4. Additional claim fee	es of \$as Applicant must subm	s a large entity small entity, it the additional claim fees or cance		
5. R Applicant has not PCT/DO/EO/920.	t submitted the required	d sequence listing pursuant to 37 C	FR 1.821-1.825. See	attached
MONTHS FROM TH	E DATE OF THIS NO TE FOR THE APPLIC)-3(d), 4 AND 5 ABOVE MUST OTICE OR BY 22 OR 32 MONT CATION, WHICHEVER IS LAT MENT.	HS (where 37 CFR 1.	495 applies) FROM
The time period set abo 1.136(a).	ove may be extended by	filing a petition and fee for extens	sion of time under the p	rovisions of 37 CFR
Annexes will be cancell	led. A processing fee valued mendments are cancelled	the Annexes MUST be submitted is will be required if submitted later the desince a translation was not provi- ority date.	han 20 or 30 months fro	om the priority date.
		to the United States Patent and Tr I.S. application no. shown above. (e mailed to the
Enclosed: PCT/DO	D/EO/917	Notice of Defective Translation	vith this response	The second and the se
PTO-875)	x. PCT/DO/EO/920 S	hakeel Ahmed	

Telephone: 703-305-3659

DECT WAIT ABLE COPY

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

I.S. APPLICATION NO.	FIRST NAMED APPLICANT ATTY. DOCKET NO.		ATTY. DOCKET NO.	
09/674436	KOTAKI	Т	101136-00021	
		INTERNATION	ERNATIONAL APPLICATION NO.	
RENT FOX KINTNER PLOTKIN (PCT/JP00/03388			
050 CONNECTICUT AVENUE N	W	I.A. FILING DATE	PRIORITY DATE	
/ASHINGTON, DC 20036 5339		26 MAY 00	31 MAY 99	
		DATE MAILED:	02 JUL 20	

CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
The application fails to comply with the requirements of 37 CFR 1.821-1.825. This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c). A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other: Other:
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help, (703) 287-0200, for PatentIn software help.
Shakeei Ahmed Telephone: 703-305-3659 FORM PCT/DO/FO/920 (March 2001)

FOR